<DOC>
	<DOCNO>NCT01405196</DOCNO>
	<brief_summary>The objective study evaluate compare efficacy 3 dose level PF-04236921 placebo subject generalize lupus use measure call Systemic Lupus Erythematosus ( SLE ) Responder Index . The study evaluate secondary exploratory measure well .</brief_summary>
	<brief_title>Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Male female subject age 18 75 year old time sign consent . Have clinical diagnosis SLE accord 1997 update revise 1982 American College Rheumatology ( ACR ) criterion . Have unequivocally positive antinuclear antibody ( ANA ) test result . Active disease screening define : SLEDAI2K score great equal 6 BILAG Level A disease equal 1 organ system ( except renal central nervous system ) BILAG B disease equal 2 organ system level A disease present . Any prior history treatment PF04236921 , antiIL6 agent ; Have receive follow within 364 day day 1 : biologic investigational agent B cell target therapy ; require 3 course systemic corticosteroid concomitant condition ; history previously untreated current evidence active untreated latent infection Tuberculosis ( TB ) , evidence prior untreated currently active TB chest radiography , reside frequent close contact individual active TB .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>multicenter</keyword>
	<keyword>dose-ranging</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>lupus .</keyword>
</DOC>